KMPHARMACEUTICAL Co.,Ltd. (KOSDAQ:225430)
South Korea · Delayed Price · Currency is KRW 2,585.00
-170.00 (-6.17%)
At close: Apr 13, 2026
KMPHARMACEUTICAL Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 15,990 | 14,475 | 17,770 | 15,631 | 22,705 |
Other Revenue | - | - | - | -0 | -0 |
| 15,990 | 14,475 | 17,770 | 15,631 | 22,705 | |
Revenue Growth (YoY) | 10.47% | -18.54% | 13.68% | -31.16% | -0.97% |
Cost of Revenue | 12,152 | 10,869 | 12,859 | 12,407 | 17,042 |
Gross Profit | 3,838 | 3,606 | 4,910 | 3,225 | 5,663 |
Selling, General & Admin | 5,437 | 4,865 | 4,976 | 3,219 | 3,948 |
Research & Development | 943.88 | 559.98 | 298.31 | 450.38 | 404.56 |
Amortization of Goodwill & Intangibles | 4.9 | 28.2 | 39.18 | 39.44 | 39.29 |
Other Operating Expenses | 84.69 | 76.4 | 59.75 | 59.04 | 59.54 |
Operating Expenses | 7,390 | 7,453 | 6,024 | 6,946 | 4,797 |
Operating Income | -3,552 | -3,848 | -1,113 | -3,722 | 866.14 |
Interest Expense | -594.16 | -582.34 | -613.68 | -384.49 | -173.49 |
Interest & Investment Income | 667 | 672.3 | 675.68 | 431.1 | 52.57 |
Earnings From Equity Investments | -445.03 | -403.23 | - | - | - |
Currency Exchange Gain (Loss) | -2.22 | -1.59 | -6.09 | -12.15 | -15.66 |
Other Non Operating Income (Expenses) | 41.89 | -100.64 | 17.67 | -16.74 | -74.01 |
EBT Excluding Unusual Items | -3,884 | -4,263 | -1,040 | -3,704 | 655.55 |
Gain (Loss) on Sale of Investments | 0.3 | 13.98 | 74.79 | -61.63 | -674.13 |
Gain (Loss) on Sale of Assets | -0 | -0.21 | 10.42 | - | 6.56 |
Asset Writedown | - | - | -9.19 | -808.27 | -501.8 |
Pretax Income | -3,884 | -4,249 | -963.76 | -4,574 | -513.83 |
Income Tax Expense | 84.19 | 323.93 | 356.29 | -649.05 | 97.36 |
Net Income | -3,968 | -4,573 | -1,320 | -3,925 | -611.19 |
Net Income to Common | -3,968 | -4,573 | -1,320 | -3,925 | -611.19 |
Shares Outstanding (Basic) | 28 | 28 | 28 | 28 | 28 |
Shares Outstanding (Diluted) | 28 | 28 | 28 | 28 | 28 |
Shares Change (YoY) | 0.21% | -0.00% | 0.18% | 0.20% | 29.80% |
EPS (Basic) | -142.00 | -164.00 | -47.34 | -141.00 | -22.00 |
EPS (Diluted) | -142.00 | -164.00 | -47.34 | -141.00 | -22.00 |
Free Cash Flow | -2,009 | -2,401 | 1,333 | -151.02 | -97.92 |
Free Cash Flow Per Share | -71.89 | -86.09 | 47.81 | -5.42 | -3.52 |
Gross Margin | 24.00% | 24.91% | 27.63% | 20.63% | 24.94% |
Operating Margin | -22.21% | -26.58% | -6.26% | -23.81% | 3.82% |
Profit Margin | -24.82% | -31.60% | -7.43% | -25.11% | -2.69% |
Free Cash Flow Margin | -12.56% | -16.59% | 7.50% | -0.97% | -0.43% |
EBITDA | -2,541 | -2,513 | 255.73 | -2,263 | 2,308 |
EBITDA Margin | -15.89% | -17.36% | 1.44% | -14.47% | 10.17% |
D&A For EBITDA | 1,010 | 1,335 | 1,369 | 1,459 | 1,442 |
EBIT | -3,552 | -3,848 | -1,113 | -3,722 | 866.14 |
EBIT Margin | -22.21% | -26.58% | -6.26% | -23.81% | 3.82% |
Advertising Expenses | 1,278 | 990.45 | 470.11 | 577.67 | 700.87 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.